Based on the PERSONALIS INC. DL-001 stock forecast from 0 analysts, the average analyst target price for PERSONALIS INC. DL-001 is not available over the next 12 months. PERSONALIS INC. DL-001’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of PERSONALIS INC. DL-001 is Neutral, which is based on 0 positive signals and 0 negative signals. At the last closing, PERSONALIS INC. DL-001’s stock price was EUR 1.27. PERSONALIS INC. DL-001’s stock price has changed by +9.96% over the past week, -5.08% over the past month and -41.47% over the last year.
No recent analyst target price found for PERSONALIS INC. DL-001
No recent average analyst rating found for PERSONALIS INC. DL-001
Company Overview PERSONALIS INC. DL-001
Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California. Address: 6600 Dumbarton Circle, Fremont, CA, United States, 94555 Read Less
Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of persona...Read More
N/A
N/A
223
N/A
EUR
Germany
Adjusted Closing Price for PERSONALIS INC. DL-001 (04X:F)
Loading...
Unadjusted Closing Price for PERSONALIS INC. DL-001 (04X:F)
Loading...
Share Trading Volume for PERSONALIS INC. DL-001 Shares
Loading...
Compare Performance of PERSONALIS INC. DL-001 Shares
Symbol
Capital Gain
Dividend Return
Total Return
Loading...
Loading...
Technical Indicators for 04X:F
Assets
Top Holdings
N/A
Top Sectors
Top Regions
Stocks Similar To PERSONALIS INC. DL-001 (Sector: )
Frequently Asked Questions About PERSONALIS INC. DL-001 (04X:F) Stock
Stock Target Advisor's fundamental analysis for PERSONALIS INC. DL-001's stock is Neutral.
Unfortunately we do not have enough data on 04X:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 04X:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 04X:F's stock to indicate if its overvalued.
The last closing price of 04X:F's stock was EUR 1.27.
Unfortunately we do not currently have any market capitalization data for 04X:F's stock.
Unfortunately we do not have enough analyst data on 04X:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains PERSONALIS INC. DL-001's stock.
As per our most recent records PERSONALIS INC. DL-001 has 223 Employees.
Sorry we do not have any infomation available on PERSONALIS INC. DL-001's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
There is nothing we particularly dislike
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 04X:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
